Elanco
ELAN
$25.72
-2.46%
Elanco Animal Health Incorporated is a global animal health company that develops, manufactures, and markets pharmaceutical products for both companion and food animals, operating in the healthcare sector's specialty and generic drug manufacturing industry. As a spin-off from Eli Lilly in 2018, Elanco has grown through strategic acquisitions, including Bayer Animal Health in 2020, positioning itself as a top-tier player in the animal health market with a diverse portfolio spanning pet health, cattle, poultry, and swine. The current investor narrative centers on Elanco's successful turnaround, highlighted by strong Q1 2026 earnings, product momentum, and raised guidance, which have driven a significant re-rating of the stock as the company demonstrates execution on its strategic plan.…
ELAN
Elanco
$25.72
Related headlines
Investment Opinion: Should I buy ELAN Today?
Based on the analysis, ELAN is rated a Buy. The thesis is that Elanco is successfully executing a turnaround, evidenced by accelerating revenue growth and a return to profitability, which is not yet fully reflected in the stock price. The analyst consensus is Strong Buy with an average target of $30.07, implying 14% upside, and the company's forward PE of 22.05x is reasonable given the projected EPS growth.
Sign up to view all
ELAN 12-Month Price Forecast
The AI assessment is bullish on ELAN, driven by the strong fundamental inflection point and attractive valuation relative to growth. The company's revenue acceleration and return to profitability are key positive signals, and the low PEG ratio suggests the market is not fully pricing in the earnings recovery. However, the high beta and near-term overextension warrant a medium confidence level. The stance would be upgraded to high confidence if the company delivers another quarter of double-digit revenue growth and raises guidance, while a downgrade to neutral would occur if growth decelerates or margins disappoint.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Elanco's 12-month outlook, with a consensus price target around $30.07 and implied upside of +16.9% versus the current price.
Average Target
$30.07
0 analysts
Implied Upside
+16.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$26 - $32
Analyst target range
The target price range spans from a low of $26.00 to a high of $32.00, with the high target suggesting potential for further upside driven by continued product momentum and margin expansion, while the low target reflects a scenario of slower growth or competitive pressures. The relatively narrow spread of $6.00 (23% of the average target) indicates moderate uncertainty, but the strong buy consensus and recent upgrades suggest analysts are increasingly confident in Elanco's execution. The stock's strong performance and positive earnings revisions support the bullish outlook, though the high beta and near-term overextension warrant caution.
Drowning in data?
Find the real signal!
Bulls vs Bears: ELAN Investment Factors
Elanco presents a compelling turnaround story with accelerating revenue growth, a return to profitability, and strong analyst support. The bull case is underpinned by Q1 2026's 14.92% revenue growth and positive EPS, which validate the execution of the strategic plan. However, the bear case highlights high volatility, elevated valuation multiples, and a lingering debt burden that could amplify downside risks. The most critical tension is whether the company can sustain its growth momentum and margin expansion to justify the current valuation, as any stumble could lead to a sharp re-rating. Currently, the evidence slightly favors the bulls given the strong fundamental inflection and analyst confidence, but the high beta and near-term overextension warrant caution.
Bullish
- Revenue growth accelerating strongly: Q1 2026 revenue grew 14.92% YoY to $1.371B, a sharp acceleration from Q4 2025's -4.2% decline, driven by strength in Pet Health ($710M) and Farm Animal ($642M). This momentum suggests the product portfolio is gaining traction and supports the turnaround narrative.
- Return to profitability in Q1 2026: Elanco posted EPS of $0.11 in Q1 2026, a significant improvement from the -$0.56 loss in Q4 2025, with net income of $57M. This marks a clear inflection point, as the company transitions from heavy losses to sustainable profitability.
- Strong buy analyst consensus: With 14 analysts, the consensus is 'Strong Buy' (mean rating 1.41), and the average target price of $30.07 implies 14% upside from the current $26.37. The high target of $32 suggests further upside potential if execution continues.
- Attractive forward valuation with PEG of 0.28: The forward PE of 22.05x and PEG ratio of 0.28 indicate the stock is reasonably valued relative to its expected earnings growth. The low PEG suggests the market is not fully pricing in the projected EPS of $1.535, offering upside if estimates are met.
Bearish
- High volatility and beta of 1.685: With a beta of 1.685, ELAN is 68.5% more volatile than the market, amplifying downside risk. The stock has experienced a max drawdown of -26.23% over the past year, indicating significant price swings that could test investor patience.
- Negative trailing earnings and thin margins: Trailing twelve-month EPS is -$0.02, and the net margin is -4.92%, reflecting ongoing profitability challenges. While Q1 2026 was positive, the company's history of losses and low operating margin (5.34%) highlight fragility in the earnings recovery.
- High valuation on sales and EV/EBITDA: The PS ratio of 2.38x and EV/EBITDA of 21.75x are elevated, suggesting the market is pricing in substantial growth. If revenue growth decelerates or margins disappoint, the stock could face multiple compression, leading to significant downside.
- Debt burden and interest expenses: With a debt-to-equity ratio of 0.61 and interest expenses of $57M in Q1 2026, Elanco carries a significant debt load. High interest costs could pressure future earnings, especially if rates remain elevated, limiting financial flexibility.
ELAN Technical Analysis
Elanco's stock is in a robust uptrend, with a 1-year price change of +92.76%, significantly outperforming the S&P 500's +18.19% over the same period. The current price of $26.37 sits at 95.1% of its 52-week range (low of $13.39, high of $27.72), indicating the stock is trading near its highs, reflecting strong momentum and investor confidence, though it also suggests potential overextension in the short term. The stock's beta of 1.685 indicates it is 68.5% more volatile than the market, amplifying both upside and downside moves.
Beta
1.69
1.69x market volatility
Max Drawdown
-26.2%
Largest decline past year
52-Week Range
$14-$28
Price range past year
Annual Return
+86.5%
Cumulative gain past year
| Period | ELAN Return | S&P 500 |
|---|---|---|
| 1m | +2.9% | +1.7% |
| 3m | +11.9% | +4.7% |
| 6m | +5.4% | +10.4% |
| 1y | +86.5% | +21.9% |
| ytd | +14.2% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ELAN Fundamental Analysis
Elanco's revenue trajectory is accelerating, with Q1 2026 revenue of $1.371 billion, up 14.92% year-over-year, compared to a 4.2% decline in Q4 2025 and a 10.3% increase in Q3 2025. The growth is driven by strong performance in Pet Health ($710 million) and Farm Animal ($642 million) segments, with Cattle contributing $316 million and Poultry $230 million. This acceleration suggests the company's product portfolio and market strategies are gaining traction, supporting the investment case for continued growth.
Quarterly Revenue
$1.4B
2026-03
Revenue YoY Growth
+14.9%
YoY Comparison
Gross Margin
57.3%
Latest Quarter
Free Cash Flow
$315000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ELAN Overvalued?
Given Elanco's trailing twelve-month net income is negative (EPS of -$0.02), the price-to-sales (PS) ratio is the primary valuation metric, currently at 2.38x, which is below the company's historical average. The forward PE of 22.05x indicates the market expects a significant earnings recovery, as the company is projected to become profitable, with estimated EPS of $1.535 for the next fiscal year. This gap between trailing losses and forward profitability suggests the market is pricing in a successful turnaround, which is supported by recent earnings strength and raised guidance.
PE
-48.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 5x~65x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
21.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are notable for Elanco. The company's debt-to-equity ratio of 0.61 and interest expenses of $57M in Q1 2026 indicate a meaningful debt load that could strain cash flows, especially if interest rates remain high. While Q1 2026 showed positive net income of $57M, the trailing twelve-month EPS is still -$0.02, and the net margin is -4.92%, highlighting that profitability is not yet fully established. Revenue concentration in the animal health market, with a mix of companion and food animals, exposes the company to sector-specific downturns, such as disease outbreaks or shifts in livestock demand, which could disrupt growth.
FAQ
The key risks of holding ELAN include: 1) Financial risk from high debt levels (debt-to-equity of 0.61) and interest expenses, which could pressure earnings if rates rise. 2) Competitive risk from larger players like Zoetis, which could impact market share. 3) Macro risk due to the high beta of 1.685, making the stock sensitive to market downturns. 4) Company-specific risk of failing to sustain growth momentum, which could lead to a de-rating. The most severe risk is a combination of these factors, potentially leading to a 49% decline to the 52-week low of $13.39.
The 12-month forecast for ELAN is bullish, with a base case target of $28-30 (50% probability), a bull case target of $30-32 (30% probability), and a bear case target of $22-26 (20% probability). The most likely scenario is the base case, which assumes continued revenue growth of 10-12% and gradual margin improvement, leading to a stock price around the analyst average of $30.07. The bull case would require faster growth and margin expansion, while the bear case would be triggered by a growth slowdown or competitive pressures.
ELAN is fairly valued to slightly undervalued based on forward metrics. The forward PE of 22.05x is reasonable for a company with expected EPS growth to $1.535, and the PEG ratio of 0.28 indicates undervaluation relative to growth. The PS ratio of 2.38x is below the company's historical average, suggesting the market is not overpaying for sales. However, the EV/EBITDA of 21.75x is elevated, reflecting the market's expectations for margin expansion. Overall, the valuation implies that the market expects a successful turnaround, and if the company delivers, the stock could re-rate higher.
ELAN appears to be a good buy for investors with a higher risk tolerance, given the strong fundamental turnaround and analyst support. The stock offers a 14% upside to the average analyst target of $30.07, and the PEG ratio of 0.28 suggests it is undervalued relative to its growth prospects. However, the high beta of 1.685 and the stock's proximity to its 52-week high introduce significant volatility risk. For investors who believe in the sustainability of the turnaround, the risk/reward is attractive, but it is not suitable for conservative investors. A pullback to the $24-25 range would offer a better entry point.
ELAN is more suitable for long-term investment, given its turnaround stage and growth potential. The company is in the early stages of a recovery, and the benefits of its strategic initiatives are likely to play out over multiple years. The high beta of 1.685 and recent price surge make it volatile for short-term trading, but for long-term investors, the PEG ratio of 0.28 and forward PE of 22x suggest that holding for at least 2-3 years could yield significant returns as earnings materialize. Short-term traders may find opportunities in the volatility, but the stock's fundamental story is best captured over a longer horizon.
